Lung Therapeutics, Inc. Funded to Address Unmet Needs in Lung Injury and Disease
Lung Therapeutics, Inc. (LTI), a pharmaceutical company focused on developing orphan drug indications for lung injury and disease, recently announced that it closed $1,550,000 of its initial Series A Preferred Stock financing.
by Isaura Santos
BIONEWS TEXAS